Background:Fulminant myocarditis(FM)is associated with high mortality and an unfavorable long-term prognosis.However,noninvasive,rapid diagnostic and monitoring methods for FM are lacking.Case summary:This report deta...Background:Fulminant myocarditis(FM)is associated with high mortality and an unfavorable long-term prognosis.However,noninvasive,rapid diagnostic and monitoring methods for FM are lacking.Case summary:This report details the case of a patient diagnosed with FM through a comprehensive assessment involving typical clinical symptoms,laboratory analyses,echocardiographic evidence,and cardiac magnetic resonance(CMR)findings.Before the patient underwent CMR,optical pumped magnetometer magnetocardiography(OPM-MCG)revealed abnormalities characteristic of substantial myocardial injury.After invasive coronary angiography,the patient’s coronary arteries were determined not to exhibit significant stenosis.Additionally,a myocardial bridge was observed in the middle segment of the anterior descending branch of the left coronary artery.Over a 7-month follow-up,the patient’s symptoms showed marked improvement,and the OPM-MCG eventually normalized,aligning with the findings indicated by the CMR.Conclusion:OPM-MCG is a valuable tool for therapy monitoring in FMs,offering a safe,non-invasive,and highly effective test for ancillary diagnostics and long-term prognostic follow-up.Additionally,MCG may potentially assist in clinical decision-making regarding the need for further interventions in patients with myocardial bridge.展开更多
Background:Breast cancer is one of the most common malignant tumors among women worldwide.Chemotherapeutic and targeted agents,as important adjuvant therapy for breast cancer,can also cause cardiotoxicity,leading to c...Background:Breast cancer is one of the most common malignant tumors among women worldwide.Chemotherapeutic and targeted agents,as important adjuvant therapy for breast cancer,can also cause cardiotoxicity,leading to cardiac dysfunction.It is essential to recognize cardiotoxicity early,cease drug exposure when appropriate,and initiate heart failure therapy.Currently,echocardiography is routinely used to monitor cardiac function during treatment.However,normal left ventricular ejection fraction(LVEF)measured by echocardiography cannot exclude cardiotoxicity.Therefore,more sensitive cardiac monitoring tools are needed.Optical pumped magnetometer-magnetocardiography(OPM-MCG)has been proved to be a noninvasive and effective means to detect and monitor myocardial injury.Case description:In this case,we presented a patient diagnosed with early breast cancer with human epidermal growth factor receptor 2(HER2)overexpression,following adjuvant therapy with paclitaxel liposomes,trastuzumab,and pertuzumab.Heart failure with reduced ejection fraction(HFr EF)occurred after five cycles of anti-HER2 therapy,which improved with chronic heart failure(CHF)treatment.The MCG scan of this patient was significantly abnormal when she developed symptomatic HFr EF,which improved gradually during CHF treatment.Conclusion:The patient's heart failure was most likely caused by HER2-targeted agents,which was reversible and could be improved with the administration of angiotensin receptor neprilysin inhibitor(ARNi)and sodium-glucose cotransporter-2 inhibitor(SGLT2i).In the future,OPMMCG may act as a safe,accurate,and efficient evaluation tool for cardiotoxicity monitoring to detect early myocardial injury in cancer patients.展开更多
基金supported by Sponsored by Beijing Nova Program(20220484222)‘Deng Feng’Training Program(DFL20220603)Project of The Beijing Lab for Cardiovascular Precision Medicine(PXM2018_014226_000013).
文摘Background:Fulminant myocarditis(FM)is associated with high mortality and an unfavorable long-term prognosis.However,noninvasive,rapid diagnostic and monitoring methods for FM are lacking.Case summary:This report details the case of a patient diagnosed with FM through a comprehensive assessment involving typical clinical symptoms,laboratory analyses,echocardiographic evidence,and cardiac magnetic resonance(CMR)findings.Before the patient underwent CMR,optical pumped magnetometer magnetocardiography(OPM-MCG)revealed abnormalities characteristic of substantial myocardial injury.After invasive coronary angiography,the patient’s coronary arteries were determined not to exhibit significant stenosis.Additionally,a myocardial bridge was observed in the middle segment of the anterior descending branch of the left coronary artery.Over a 7-month follow-up,the patient’s symptoms showed marked improvement,and the OPM-MCG eventually normalized,aligning with the findings indicated by the CMR.Conclusion:OPM-MCG is a valuable tool for therapy monitoring in FMs,offering a safe,non-invasive,and highly effective test for ancillary diagnostics and long-term prognostic follow-up.Additionally,MCG may potentially assist in clinical decision-making regarding the need for further interventions in patients with myocardial bridge.
基金supported by the Capital's Funds for Health Improvement and Research(2024-2-2066)the Beijing Hospitals Authority“sailing”Program(YGLX202323)+4 种基金the Beijing Nova Program(grant number 20220484222)the Coordinated Innovation of Scientific and Technological in Beijing-TianjinHebei Region(grant number Z231100003923008)the Beijing Hospitals Authority's Ascent Plan(grant number DFL20220603)the Project of The Beijing Lab for Cardiovascular Precision Medicine(grant number PXM2018_014226_000013)the High-level Public Health Technical Talent Construction Project of Beijing Municipal Health Commission(Leading Talent-02-01)
文摘Background:Breast cancer is one of the most common malignant tumors among women worldwide.Chemotherapeutic and targeted agents,as important adjuvant therapy for breast cancer,can also cause cardiotoxicity,leading to cardiac dysfunction.It is essential to recognize cardiotoxicity early,cease drug exposure when appropriate,and initiate heart failure therapy.Currently,echocardiography is routinely used to monitor cardiac function during treatment.However,normal left ventricular ejection fraction(LVEF)measured by echocardiography cannot exclude cardiotoxicity.Therefore,more sensitive cardiac monitoring tools are needed.Optical pumped magnetometer-magnetocardiography(OPM-MCG)has been proved to be a noninvasive and effective means to detect and monitor myocardial injury.Case description:In this case,we presented a patient diagnosed with early breast cancer with human epidermal growth factor receptor 2(HER2)overexpression,following adjuvant therapy with paclitaxel liposomes,trastuzumab,and pertuzumab.Heart failure with reduced ejection fraction(HFr EF)occurred after five cycles of anti-HER2 therapy,which improved with chronic heart failure(CHF)treatment.The MCG scan of this patient was significantly abnormal when she developed symptomatic HFr EF,which improved gradually during CHF treatment.Conclusion:The patient's heart failure was most likely caused by HER2-targeted agents,which was reversible and could be improved with the administration of angiotensin receptor neprilysin inhibitor(ARNi)and sodium-glucose cotransporter-2 inhibitor(SGLT2i).In the future,OPMMCG may act as a safe,accurate,and efficient evaluation tool for cardiotoxicity monitoring to detect early myocardial injury in cancer patients.
